Iterum Therapeutics plc
ITRM
$0.6833
-$0.0377-5.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.26% | 31.12% | 46.76% | -57.18% | 59.18% |
| Total Depreciation and Amortization | 4,287.50% | 4,885.71% | -40.68% | -98.17% | -98.17% |
| Total Amortization of Deferred Charges | -100.00% | -65.91% | -339.25% | 331.81% | -2.57% |
| Total Other Non-Cash Items | 38.30% | 29.50% | 520.18% | 107.57% | -34.65% |
| Change in Net Operating Assets | 95.09% | 96.57% | 38.13% | -101.23% | -288.82% |
| Cash from Operations | 29.71% | 76.61% | 66.86% | 71.16% | 11.44% |
| Capital Expenditure | 100.00% | -- | -- | -100.00% | 87.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -91.87% | 1,496.64% | -3.76% |
| Cash from Investing | -100.00% | -100.03% | -91.87% | 1,483.33% | -3.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2,965.87% | -11.92% | 2,256.03% | 54,200.00% | -16.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2,965.87% | -216.23% | 2,256.03% | 54,200.00% | -16.50% |
| Foreign Exchange rate Adjustments | 127.78% | 14.81% | 85.71% | -21.74% | -50.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 115.50% | -970.49% | 754.10% | 194.53% | 22.09% |